Page 125 - Haematologica Vol. 109 - July 2024

ARTICLE - Cytotoxic reprogramming for BiTE immunotherapy M. Casey et al. AB
CD
E
F
Figure 5. Treatment with recombinant IL-21 drives cytotoxic T-cell programming in the myeloma bone marrow. (A) Schematic illustrates the experimental design for murine recombinant interleukin-21 (rIL-21) treatment in the preclinical Vk14451 myeloma model. (B) Representative flow cytometry plots (left) and graphs showing frequencies (right) of EGFP+ tumor cells in the bone marrow (BM). (C) Graphs showing numbers of indicated immune subsets in the myeloma BM. (D) Graphs showing plasma levels of interferon-γ (IFN-γ) (left) and granzyme B (Gzm B) (right) 6 hours after the second injection of rIL-21. (E, F) Representative flow cytometry plots (Ieft) and graphs (right) showing frequencies of CD8 T cells (E) and CD4 T cells (F) expressing CD226 and Gzm B in the myeloma BM. Data are shown as box-and-whisker plots pooled from 2 experiments (N=8 per group). Differences were tested for statistical significance using a Mann-Whitney U test. *P<0.05; ***P<0.001. SSC: side scatter; EGFP: enhanced green fluorescent protein; PBS: phosphate-buffered saline.
Haematologica | 109 July 2024
2139